Hanhui Pharma is committed to the specialized promotion of domestic and international new chemical entities and innovator drugs, providing Chinese doctors and patients with the medical products of the highest quality, improving national health, extending human life expectancy and enhancing quality of life.
Hanhui Pharmaceuticals Co., Ltd (formerly Hisun-Pfizer Pharmaceuticals Co., Ltd.) was established in 2012 by Hisun Pharmaceutical Co., Ltd. in a joint venture with global pharmaceutical giant, Pfizer Pharmaceuticals. At present, Hanhui Pharma has become a 100% subsidiary of Hisun.
With the strong support of Hisun, Hanhui Pharma will grow into a leading enterprise in the pharmaceutical industry in China, driven by continuous innovation and integration, based on excellent operating efficiency and oriented by customer value.
Hanhui Pharma has built a manufacturing site that meets the global standards, and developed into a leading new CSO platform in China. At present, more than 60 kinds of products are supplied in the Chinese market, including the world-leading innovators, the products won the National Science and Technology Invention Award and the support of major National Programs for Science and Technology, covering many fields such as tumor, cardio-cerebrovascular and metabolism, anti-infection, respiratory, hormone, immunosuppressant, etc.
